Pharmaceutical Product Develop (PPDI) Cash Flow Statement

Click line-items for a historical chart and %

Net income	118.4M
Depreciation and amortization	50.5M
Equity compensation expense	15.33M
Loss (income) from equity investment, net of taxes	-9.71M
Benefit for deferred income taxes	-4.88M
Other	-1.16M
Net change in operating assets and liabilities	-36.79M
Net cash provided by operating activities	150.74M
Purchases of property and equipment	-61.7M
Proceeds from sale of property and equipment	67K
Purchases of investments	-1.53M
Maturities and sales of investments	91.8M
Purchases of other investments	-8.02M
Proceeds from liquidation of other investments	539K
Net cash paid for acquisitions	-7.94M
Changes in restricted cash	7.94M
Proceeds from sale of business	0
Advances to related party	-7.55M
Net cash provided by investing activities	13.61M
Proceeds from exercise of stock options and employee stock purchase plan	31.48M
Income tax benefit from exercise of stock options and disqualifying dispositions of stock	1.24M
Cash and cash equivalents contributed to Furiex Pharmaceuticals, Inc.	0
Repurchase of common stock	-200M
Cash dividends paid	-52.82M
Net cash used in financing activities	-220.11M
Effect of exchange rate changes on cash and cash equivalents	-7.07M
Net increase (decrease) in cash and cash equivalents	-62.83M
Cash and cash equivalents, beginning of the period	479.57M
Cash and cash equivalents, end of the period	416.75M

Entities mentioned with PPDI

View All Entities